Michael Haller, M.D.
Dr. Michael Haller is a pediatric endocrinologist with a passion for patient care, teaching, and research. Dr. Haller’s research focuses on predicting, preventing, and reversing type 1 diabetes through a team approach that emphasizes translating findings from the laboratory bench to the patient’s bedside in a timely manner. Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet and The Environmental Determinants of Diabetes in Youth (TEDDY) study.
Dr. Haller currently serves as the Principal Investigator (PI) for the TrialNet ATG/GCSF study funded collaboratively by the NIH, the Helmsley Trust, and Sanofi. He also serves as a co-investigator for all other TrialNet studies at the University of Florida, and as the Chair of the Clinical Implementation Committee for the international TEDDY study.
Dr. Haller has also served as the PI of studies aimed at using autologous umbilical cord blood stem cells as a potential therapy for type 1 diabetes. Dr. Haller, in collaboration with Dr. Brusko continues to explore the potential for developing cord blood based therapies. Dr. Brusko is perfecting techniques that allow for the expansion of cord blood cells that help to regulate the immune system and Dr. Haller hopes to use these cells in future clinical trials.
In 2008, Dr. Haller, and his colleagues Dr. Desmond Schatz and Dr. Mark Atkinson received the JDRF’s highest award, the Mary Tyler Moore and S.Robert Levine Excellence in Clinical Research Award, for their team approach to developing therapies for type 1 diabetes. In 2009, Dr. Haller and his colleagues received the ADA Cure Award and in 2010 Dr. Haller received the ISPAD Young Investigator Award.
Michael Haller, MD, and the entire team of type 1 diabetes researchers at the University of Florida are dedicated to the development of safe and effective therapies to prevent and reverse Type 1 diabetes. As a clinician-scientist, Dr. Haller’s efforts are focused on providing exemplary clinical care for children with Type 1 diabetes while working to speed the translation of information learned from animal models of Type 1 diabetes to the development of therapies for patients.
Given the complex nature of Type 1 diabetes, Dr. Haller believes that combination or cocktail therapy approaches are necessary to effectively intervene in the autoimmune process. In addition, Dr. Haller feels that the use of drugs already on the market with known risks and benefits to treat other diseases should be explored to speed the development of a cure. In collaboration with Drs. Mark Atkinson and Desmond Schatz, Dr. Haller’s research efforts are focused on combining cell therapies, immunomodulating drugs, and beta-cell regenerative agents. Data demonstrate that some combinations of these drugs can reverse diabetes in nearly 90% of newly diagnosed mice. Combination therapy studies with ATG and GCSF have already demonstrated their ability to preserve beta cell function in patients with established type 1 diabetes and confirmatory studies of ATG and GCSF in newly diagnosed patients will begin in 2014.
Dr. Haller participates in the NIH funded Type 1 Diabetes TrialNet and TEDDY consortia, performing studies aimed at testing additional therapies for reversing Type 1 diabetes and unlocking the mystery of what environmental triggers cause Type 1 diabetes.
Current Clinical Trials
Additional publications can be found in PubMed.
- Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease.
Elding Larsson H, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, Lernmark Å, Rewers M, Simell O, She JX, Ziegler A, Haller MJ; TEDDY Study Group. Pediatr Diabetes. 2014
Mar;15(2):118-26. doi: 10.1111/pedi.12066. Epub 2013 Aug 27.
- Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis.
Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ; Pediatric Diabetes Consortium.
Pediatr Diabetes. 2014 Jun;15(4):287-93. doi: 10.1111/pedi.12068. Epub 2013 Aug 15.
- Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.
Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA.
Biol Blood Marrow Transplant. 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20
- Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research.
Gan MJ, Albanese-O’Neill A, Haller MJ.
Curr Probl Pediatr Adolesc Health Care. 2012 Nov-Dec;42(10):269-91. doi: 10.1016/j.cppeds.2012.07.002. Review.
- Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA.Diabetes. 2009 Oct;58(10):2277-84. doi: 10.2337/db09-0557. Epub 2009 Jul 23.